Leor Roseman is a psychedelic researcher whose work explores both the individual and collective dimensions of psychedelic experience — from DMT interruption studies to intergroup healing in the Israeli-Palestinian context. In this interview, we discuss how psychedelics may open space not only for personal transformation, but also for collective reconciliation.

Psychedelic therapy can offer spiritual validation and gender euphoria for trans and non-binary people — Jae Sevelius explains what truly affirming psychedelic care means in practice.

Colorado is the second U.S. state to legalize the therapeutic use of psilocybin mushrooms. During the Psychedelic Science conference in June 2025, Drugreporter visited ETC Hospitality in Golden, Colorado — a newly licensed natural medicine healing center — to see how psilocybin-assisted psychotherapy will be practiced in real-world settings.

Clinical psychologist Brian Richards, Psy.D., explains how psychedelics can transform palliative care—from creating truly healing therapeutic spaces to supporting patients facing the end of life.

Two spiritual leaders from different faiths reveal how psychedelics are transforming their understanding of religion, community, and each other — watch Drugreporter’s new interview!

In Drugreporter’s new interview, trauma expert Bessel van der Kolk, MD explores how the body stores trauma and why integration is essential for healing in psychedelic therapy.

In Drugreporter’s new interview, German author Norman Ohler explores how psychedelics became entangled with war, power, and propaganda.

In Drugreporter’s new interview, Dominique Mendiola, Senior Director of Colorado’s Natural Medicine Division, shares how Colorado is shaping the next chapter of psychedelic regulation in the United States.

In Drugreporter’s new interview, Bill Richards, a pioneering psychologist and theologian who has explored the therapeutic and spiritual dimensions of psychedelics since the 1960s, reflects on the rebirth of psychedelic research and the enduring healing power of mystical experience.

In Drugreporter’s interview from Psychedelic Science 2025, Rick Doblin looks back on four decades of psychedelic activism and discusses the future after the FDA’s MDMA therapy rejection.